Various types of cancer have been revolutionized in the therapy field by osimertinib and pembrolizumab, which are two crucial focused treatments.Diving into a comparison study of the two drugs—osimertinib and pembrolizumab—the article highlights their ways of operation, effectiveness, side effects, and clinical applications.Osimertinib, being an oral EGFR tyrosine kinase inhibitor (EGFR-TKI), is to target the EGFR mutation present in NSCLC (NSCLC).As an immune checkpoint modulator, pembrolizumab blocks the interaction between PD-1 and PD-L1 molecules, thereby enabling the immune response to identify and destroy cancer cells.In the treatment of NSCLC, both…
